CN107076747B - 分子乳房摄影术 - Google Patents

分子乳房摄影术 Download PDF

Info

Publication number
CN107076747B
CN107076747B CN201580039837.XA CN201580039837A CN107076747B CN 107076747 B CN107076747 B CN 107076747B CN 201580039837 A CN201580039837 A CN 201580039837A CN 107076747 B CN107076747 B CN 107076747B
Authority
CN
China
Prior art keywords
mir
breast
individual
carcinoma
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580039837.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107076747A (zh
Inventor
书志·陈
史蒂文·C·夸伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atosa Therapeutics
Original Assignee
Atosa Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atosa Therapeutics filed Critical Atosa Therapeutics
Publication of CN107076747A publication Critical patent/CN107076747A/zh
Application granted granted Critical
Publication of CN107076747B publication Critical patent/CN107076747B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580039837.XA 2014-06-04 2015-06-02 分子乳房摄影术 Expired - Fee Related CN107076747B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007830P 2014-06-04 2014-06-04
US62/007,830 2014-06-04
PCT/US2015/033827 WO2015187727A2 (en) 2014-06-04 2015-06-02 Molecular mammography

Publications (2)

Publication Number Publication Date
CN107076747A CN107076747A (zh) 2017-08-18
CN107076747B true CN107076747B (zh) 2021-02-02

Family

ID=54767566

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580039837.XA Expired - Fee Related CN107076747B (zh) 2014-06-04 2015-06-02 分子乳房摄影术

Country Status (5)

Country Link
US (1) US20170145515A1 (https=)
EP (1) EP3152579A4 (https=)
JP (1) JP6757935B2 (https=)
CN (1) CN107076747B (https=)
WO (1) WO2015187727A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107012199A (zh) * 2016-01-28 2017-08-04 上海市东方医院 一种在血浆和血清中检测miRNA的方法
JP6980219B2 (ja) * 2016-08-22 2021-12-15 いであ株式会社 がんを検出、又はがんの進行期を判定する方法
WO2018098379A1 (en) * 2016-11-22 2018-05-31 Prime Genomics, Inc. Methods for cancer detection
TWI793165B (zh) 2017-09-11 2023-02-21 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
JP7108715B2 (ja) * 2018-01-25 2022-07-28 パー ホール 乳房障害の治療をモニターするための組成物および方法
GB201907999D0 (en) * 2019-06-05 2019-07-17 Cambridge Entpr Breast cancer detection methods
MX2022000203A (es) 2019-07-03 2022-03-22 Atossa Therapeutics Inc Composiciones de liberacion sostenida de endoxifeno.
CN110760513A (zh) * 2019-08-23 2020-02-07 西北工业大学 靶向三阴性乳腺癌细胞PENK基因的miR-506及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042660A2 (en) * 2001-11-14 2003-05-22 Sirbasku David A Screening method for predicting susceptibility to breast cancer
WO2007140352A2 (en) * 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798266A (en) * 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
CA2477828A1 (en) * 2002-03-15 2003-09-25 Cytyc Health Corporation Method of diagnosis and treatment of breast lesions
US8738124B2 (en) * 2007-12-11 2014-05-27 Epi-Sci, Llc Electrical bioimpedance analysis as a biomarker of breast density and/or breast cancer risk
EP2358912B1 (en) * 2008-10-30 2016-10-12 Caris Life Sciences Switzerland Holdings GmbH Methods for assessing rna patterns
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
WO2011137288A2 (en) * 2010-04-30 2011-11-03 The Ohio State University Mirna networks in cancers and leukemias and uses thereof
WO2013063147A1 (en) * 2011-10-24 2013-05-02 Atossa Genetics, Inc. Absorbent paper and use thereof for breast cancer detection
US20130115629A1 (en) * 2011-10-24 2013-05-09 Atossa Genetics, Inc. Methods of breast cancer detection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042660A2 (en) * 2001-11-14 2003-05-22 Sirbasku David A Screening method for predicting susceptibility to breast cancer
WO2007140352A2 (en) * 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Oxytocin: bringing magic into nipple aspiration.;K.P.M.Suijkerbuijk, et al.;《Annals of Oncology》;20071001;第18卷(第10期);第1743页 *
Serum Biomarkers to Differentiate Benign and Malignant Mammographic Lesions.;Susanna Shin, et al.;《JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS》;20070531;第204卷(第5期);摘要，第1066-1068页 *

Also Published As

Publication number Publication date
EP3152579A4 (en) 2018-01-17
CN107076747A (zh) 2017-08-18
JP6757935B2 (ja) 2020-09-23
WO2015187727A3 (en) 2016-01-21
JP2017527775A (ja) 2017-09-21
US20170145515A1 (en) 2017-05-25
WO2015187727A2 (en) 2015-12-10
EP3152579A2 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
CN107076747B (zh) 分子乳房摄影术
Zhu et al. Potential clinical utility of liquid biopsies in ovarian cancer
Takeshita et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma
EP2809801B1 (en) Non-invasive cancer diagnosis
Jovčevska Sequencing the next generation of glioblastomas
JP2019528081A (ja) 子宮内膜症についてのバイオマーカーとしてのマイクロｒｎａ
Zhang et al. Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma
JP2014516543A (ja) 癌再発の予後予測のための方法および装置
EP3122905B1 (en) Circulating micrornas as biomarkers for endometriosis
JP2022523366A (ja) 癌の診断及び予後に関するバイオマーカーパネル
GB2536374A (en) Biomarkers useful for detection of types, grades and stages of human breast cancer
Bhardwaj et al. Liquid biopsy in ovarian cancer
Andreasen Molecular features of adenoid cystic carcinoma with an emphasis on microRNA expression.
WO2011154008A1 (en) Microrna classification of thyroid follicular neoplasia
Senaratne et al. Clinical value of circulating microRNAs in diagnosis and prognosis of pancreatic cancer: A systematic review
EP3889610A1 (en) Biomarker composition for predicting cancer malignant prognosis induced by microplastic exposure
KR102096499B1 (ko) 대장암 진단 또는 재발 예측을 위한 마이크로rna-3960 및 이의 용도
Huang et al. Clinical translational research of liquid biopsy applications in prostate cancer and other urological cancers
CN103773761B (zh) 检测胃癌的血清/血浆微小rna标志物及其应用
Gordon et al. Genomic medicine for cancer diagnosis
RU2547583C2 (ru) Способ диагностики рака молочной железы
González Martínez El papel de los microARNs en el diagnóstico y pronóstico del cáncer de mama
Duréndez Sáez Liquid Biopsy in non-small cell lung cancer: exosomes as a tool for the study of biomarkers.
Bajpai et al. Biomarkers of Esophageal Cancers and Precancerous Lesions
Bakhsh Deep Sequencing Towards Detection of Novel Exosomal miRNA for Prognosis of Colorectal Cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Washington State

Applicant after: Atosa therapeutics

Address before: Washington State

Applicant before: ATOSSA GENETICS, Inc.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210202

Termination date: 20210602

CF01 Termination of patent right due to non-payment of annual fee